Liposomal Bupivacaine may not reduce pain after abdominal wall reconstruction surgery

It was a single-center, double-blind, placebo-controlled prospective study conducted between July 2018 and November 2019. Researchers included a total of 164 patients who underwent open, elective, ventral hernia repairs with mesh placed in the retromuscular position. Researchers randomly performed transversus abdominis plane block with liposomal bupivacaine (n=57), simple bupivacaine (n=55), or normal saline (placebo, n=52). The major outcome assessed was the opioid requirements in the first 72 hours after surgery. Researchers also assessed the total inpatient opioid use, pain scores determined using a 100 mm visual analogue scale, length of hospital stay, and patient-reported quality of life.

Upon analysis, the researchers found no differences in the total opioid used in the first 72 hours after surgery as measured by morphine milligram equivalents when liposomal bupivacaine compared to simple bupivacaine and placebo (325 ± 225 vs 350 ± 284 vs 310 ± 272, respectively). Similarly, they found no differences in total inpatient opioid use, pain scores, length of stay, and patient-reported quality of life.

The authors concluded, "There are no apparent clinical benefits to using liposomal bupivacaine transversus abdominis plane block when compared to simple bupivacaine and placebo for open abdominal wall reconstruction".

For further information:

https://journals.lww.com/annalsofsurgery/Abstract/9000/The_Efficacy_of_Liposomal_Bupivacaine_On.93890.aspx